A Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and Above

NCT04847102 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

28000

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19
SARS-CoV-2

Interventions

BIOLOGICAL: SARS-CoV-2 mRNA Vaccine
BIOLOGICAL: Placebo

Sponsor

Walvax Biotechnology Co., Ltd.

Collaborators

[object Object]
[object Object]